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OBJECTIVES Our goal was to study metabolic energy stores and lactate content in chronic reversibly and
irreversibly dysfunctional myocardium.
BACKGROUND It is unknown whether metabolism is deranged in chronic reversibly and irreversibly
dysfunctional myocardium in humans. Semiquantitative histological examinations have
shown altered mitochondrial morphology and glycogen accumulation in dysfunctional
regions.
METHODS We studied 25 patients with a mean ejection fraction of 38 6 9% scheduled for coronary
artery bypass surgery. Regional perfusion and metabolism were assessed by positron emission
tomography, and regional function was assessed by echocardiography. Perioperative myocar-
dial biopsies were obtained from a control region and from a dysfunctional region. We
analyzed biopsies for contents of noncollagen protein (NCP), ATP, ADP, AMP, glycogen
and lactate. Six months after surgery we assessed wall motion by echocardiography to group
patients in those with (n 5 11) and without (n 5 14) functional improvement.
RESULTS Reversibly dysfunctional myocardium had reduced perfusion (0.59 6 0.16 vs. 0.69 6 0.20
ml/g/min, p , 0.05), similar glucose-tracer uptake (92 6 12 and 95 6 14%), ATP/ADP ratio
(2.4 6 1.1 and 2.4 6 0.7), glycogen content (631 6 174 and 632 6 148 nmol/mg NCP) and
lactate levels (59 6 27 and 52 6 29 nmol/mg NCP) compared with control regions.
Irreversibly dysfunctional regions (n 5 14) had severely reduced perfusion (0.48 6 0.15 vs.
0.72 6 0.12 ml/g/min, p , 0.001) and glucose-tracer uptake (52 6 16 vs. 94 6 15%, p ,
0.001), reduced ATP/ADP ratio (1.5 6 0.9 vs. 2.3 6 0.9, p , 0.05), similar glycogen content
(579 6 265 vs. 593 6 127 nmol/mg NCP) and increased lactate levels (114 6 52 vs. 89 6
24 nmol/mg NCP, p , 0.01) compared with control regions.
CONCLUSIONS Contents of metabolic energy stores and lactate in chronic reversibly dysfunctional myocar-
dium were preserved. In contrast, energy stores were depleted in myocardium without
functional recovery after revascularization. (J Am Coll Cardiol 2001;37:100–8) © 2001 by
the American College of Cardiology
Improvement of myocardial function after coronary artery
bypass grafting (CABG) can be predicted by positron
emission tomography (PET) in patients with chronic left
ventricular dysfunction caused by coronary artery disease
(1). Myocardium with chronic reversible dysfunction (“hi-
bernating myocardium”) has normal to moderately reduced
perfusion and preserved or increased uptake of the glucose-
tracer 18F-fluoro-2-deoxyglucose (FDG), while chronic ir-
reversibly dysfunctional myocardium exhibits reduced per-
fusion and metabolism (1–3). Chronic reversible myocardial
dysfunction is associated with episodes of myocardial isch-
emia (4,5), but the effect of repetitive ischemic attacks on
myocardial metabolism remains unclear (6). The increase in
FDG uptake relative to flow in chronic reversibly dysfunc-
tional myocardium has been suggested to reflect increased
anaerobic glycolysis due to ischemia (7), but the explanation
appears unlikely in view of the normal or nearly normal
levels of myocardial blood flow (MBF) (2–4,8) and oxygen
consumption (8,9). Noninvasive estimates of myocardial
perfusion and substrate metabolism achieved by PET may
be inaccurate due to partial volume effects (10) and meth-
odological limitations of the tracer kinetic models (11–13).
Increased glycogen stores in chronic reversibly dysfunctional
myocardium (4,14–17) may reflect that glucose is diverted
away from energy generating pathways toward storage.
However, glycogen accumulation is not a consistent finding
(18,19), and quantitative analyses on glycogen content are
not available.
In this study we analyzed biopsies from dysfunctional
myocardium of patients with stable coronary artery disease
and left ventricular dysfunction for energy stores and me-
tabolites. Our aims were to study whether chronic reversibly
dysfunctional myocardium exhibited any metabolic evidence
of ischemia in terms of deranged energy stores and metab-
olites. We also studied whether myocardial energy stores
and metabolites differed between reversibly and irreversibly
dysfunctional myocardium. Myocardial glycogen content
was measured quantitatively to clarify whether glucose
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uptake in chronic dysfunctional myocardium is used for
increased storage of glycogen.
METHODS
Patients. We included consecutive patients referred to
CABG with left ventricular ejection fraction by ventricu-
lography below 50% and dysfunction in the anterior or
lateral left ventricular wall. Patients with myocardial infarc-
tion within the last 3 months, aneurysm, unstable angina,
diabetes mellitus, previous CABG, cardiac valve disease and
congenital heart disease were excluded. The study protocol
was approved by the local ethics committee. Informed
written consent was obtained from all patients.
We included 36 patients, but in three patients biopsies
were not available for logistic reasons. In three patients the
amount of biopsy material was insufficient for biopsy anal-
ysis. From the remaining 30 patients we used the biopsies
from 26 patients for analyses of metabolites and biopsies
from four patients for a substudy of histology.
Study design. Preoperatively, we performed echocardiog-
raphy to assess regional wall motion and PET to measure
regional myocardial perfusion and FDG uptake. During
surgery myocardial biopsies were taken guided by trans-
esophageal echocardiography from a dysfunctional region
and from a control region with normal wall motion to
eliminate the interindividual variation in myocardial con-
tents of metabolites (20,21). Six months postoperatively we
studied graft patency by coronary angiography and wall
motion by echocardiography.
Echocardiographic protocol. We obtained echocardio-
graphic images in six standard views (22). Digital echocar-
diographic recordings and analyses were performed on a
Vingmed CFM 750 ultrasonic scanner (Vingmed, Horten,
Norway) with a 3.25 MHz transducer connected to a
computer equipped with Echopac analysis software (Ving-
med, Horten, Norway). Images were digitized on-line (R to
R-wave). Regional wall motion scoring was evaluated using
the 16-segment model (22). Wall motion score index
(WMSI) was calculated in each patient as the sum of
segmental scores divided by 16. The initial and follow-up
rest studies were displayed side by side in a quad screen
digital format and interpreted by an observer blinded to
clinical and angiographic data. Improvement of function
was defined as improvement by at least one full grade in two
adjacent dysfunctional segments on postoperative follow-
up. We calculated left ventricular volumes and ejection
fraction by the modified Simpson’s method (23) and mea-
sured diastolic and systolic wall thickness in biopsy regions
on transesophageal and transthoracic echocardiographic im-
ages. Systolic wall thickening was calculated as [(systolic-
diastolic wall thickness)/diastolic wall thickness] 3 100%.
PET. Patients were studied during their usual medication.
We used whole body PET (Model EXACT HR 961,
Siemens/CTI, Knoxville, Tennessee). A 20 min attenuation
scan was performed followed by intravenous injection of
13N-ammonia (740 MBq in 20 ml saline) over 30 s with
acquisition of a dynamic sequence of images (12 frames of
10 s). For the FDG study patients were given 50 g of oral
glucose administered as a 100 ml 50% glucose beverage 1 h
before intravenous administration of 370 MBq of FDG over
1 min. Thirty minutes after injection of FDG, three 10-min
frames were obtained for semiquantitative measurement of
myocardial FDG uptake. Myocardial blood flow in the
segments biopsied was calculated as previously described
(24). We used diastolic and systolic echocardiographic
measurements for assessment of average wall thickness for
partial volume correction, assuming an average systolic
duration of one-third of the RR-interval. Relative uptake of
FDG was assigned to be 100% in the region with the
highest MBF. In biopsy regions FDG uptake was expressed
as percentages of this activity.
Perioperative myocardial biopsies. From each patient we
obtained two transmural myocardial biopsies, one from a
dysfunctional region in the anterior or lateral left ventricular
wall and one from a control region with normal wall
motion. We determined biopsy location before cardiopul-
monary bypass by transesophageal echocardiography using a
multiplane, two-element annular phased-array 5 MHz
transducer (Vingmed, Horten, Norway). After initiation of
cardiopulmonary bypass, but before cardioplegia was insti-
tuted, biopsies were taken with a 20-mm, 14-gauge Tru-Cut
biopsy needle (Baxter Healthcare Corporation, Illinois).
Metabolites in myocardial biopsies. In 26 patients biop-
sies were frozen in liquid nitrogen within 10 s. We analyzed
biopsies for contents of ATP, ADP, AMP, glycogen, lactate
and noncollagen protein (NCP) as previously described
(21,25–27). Metabolites were related to NCP. All biopsy
analyses were performed blindly.
Histological study. We used myocardial biopsies from
four patients for histology. Biopsies were immediately fixed
in 4% buffered formalin for 1 h, dehydrated in ethanol,
embedded in paraffin and cut in 3 mm slices. We stained
tissue sections with periodic acid Schiff (PAS) to detect
glycogen and performed amylase digestion on an adjacent
section followed by PAS staining to verify that the PAS
positive material was glycogen. Staining with picrosirius red
was performed to detect fibrosis. The histological sections
were evaluated qualitatively with regard to glycogen content
and degree of fibrosis.
Coronary angiography at follow-up. Graft-patency to
biopsy regions were examined by angiography 6 months
postoperatively, but 4 of the 30 patients declined coronary
Abbreviations and Acronyms
CABG 5 coronary artery bypass grafting
FDG 5 18F-fluoro-2-deoxyglucose
MBF 5 myocardial blood flow
NCP 5 noncollagen protein
PAS 5 periodic acid Schiff
PET 5 positron emission tomography
WMSI 5 wall motion score index
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angiography at follow-up. A patent graft was required to
have Thrombolysis In Myocardial Infarction (TIMI) grade
3 flow (28).
Statistics. We analyzed data by a two-way repeated mea-
sures analysis of variance. We tested for interaction, that is,
differences (control and dysfunctional myocardium), in the
reversibly dysfunctional group versus differences in the
irreversibly dysfunctional group. If this was not significant
we tested for main effects. Student t test was used to assess
any potential differences between control regions in the two
groups. We calculated the 95% confidence intervals for the
mean difference between dysfunctional and control regions
for each group. Correlation between parameters was tested
by least squares linear regression analysis and the correlation
coefficient r. We used the statistical software program SPSS
8.0 for statistical analyses. All values are reported as mean 6
standard deviation or 95% confidence interval for the mean.
A p value , 0.05 was considered statistically significant.
RESULTS
Coronary angiography. We excluded one patient at
follow-up because coronary angiography identified an oc-
cluded graft to a dysfunctional biopsy region. In the remain-
ing 25 patients with follow-up angiography, all grafts to
biopsy regions had TIMI grade 3 flow.
Patients. Preoperative characteristics for the 25 patients in
the metabolite and 4 patients in the histological study are
shown in Table 1. Patients with and without reversible
dysfunction did not differ with regard to mean age, gender,
incidence of previous acute myocardial infarction, number
of diseased vessels and ejection fraction. Patients with
irreversible dysfunction had higher left ventricular end
diastolic volumes. This was accompanied by a trend toward
a higher incidence of Q-waves on the electrocardiogram in
this group of patients (p 5 0.07). Treatment with long-
acting nitrates was more common among patients with
reversible dysfunction than those with irreversible dysfunc-
tion (11/11 vs. 7/14, p , 0.01). Other medication and risk
factors did not differ between groups.
Regional and global left ventricular function (Table 1).
At follow-up 6 months after CABG, wall motion had
improved in the dysfunctional biopsy region in 11 of the 25
patients in the metabolite study. In spite of reduced systolic
wall thickening in reversibly dysfunctional regions com-
pared with control (9 6 4% vs. 24 6 8%, p , 0.001),
average wall thickness in reversibly dysfunctional regions did
not differ from control regions (12 6 2 mm and 12 6
2 mm). Irreversibly dysfunctional regions had reduced
systolic wall thickening (8 6 8% vs. 30 6 14%, p , 0.001)
and average wall thickness (8 6 2 mm vs. 11 6 2 mm, p ,
0.001) compared with control regions.
Ejection fraction did not differ between baseline and
follow-up for patients with reversible dysfunction (preoper-
ative 39 6 7% and postoperative 42 6 7%, p 5 0.11), but
WMSI improved from 1.8 6 0.3 to 1.7 6 0.2 (p , 0.05).
For patients with irreversible dysfunction, ejection fraction
did not differ between baseline and follow-up (preoperative
36 6 8% and postoperative 33 6 7%, p 5 0.20); however,
WMSI decreased from 1.8 6 0.3 to 1.9 6 0.3 (p , 0.05).
MBF and FDG uptake. The time from PET to surgery
ranged from 4 to 94 days with a median of 14 days. Two
patients were not examined by PET. One declined, and
another was not studied for logistic reasons. Myocardial
blood flow was reduced in reversibly dysfunctional myocar-
dium compared with control regions (0.75 6 0.19 vs.
0.65 6 0.16 ml/g/min, p , 0.05). In irreversibly dysfunc-
tional regions MBF was lower than control (0.38 6 0.08 vs.
0.78 6 0.16 ml/g/min, p , 0.001) and reversibly dysfunc-
tional regions (p , 0.05). Partial volume correction did not
alter the relation between regions (Fig. 1). Correction for
differences in the amount of fibrosis between regions, that
is, NCP/wet weight, yielded similar estimates for MBF in
reversibly dysfunctional regions and control regions (5.39 6
2.52 and 5.32 6 1.35 ml/mg NCP/min), whereas irrevers-
ibly dysfunctional regions perfusion had reduced perfusion
compared with control regions (4.55 6 1.46 ml/mg NCP/
min vs. 6.31 6 2.09 ml/mg NCP/min, p , 0.01) and
reversibly dysfunctional regions (p , 0.05). Relative FDG
uptake was similar in control and reversibly dysfunctional
regions but reduced in irreversibly dysfunctional myocar-
dium compared with control regions (Fig. 1).
Noncollagen protein (Table 2). A trend towards a lower
NCP per wet weight (ww) was observed in reversibly
dysfunctional myocardium compared with control regions
(p 5 0.06). Noncollagen protein/ww in irreversibly dysfunc-
tional myocardium was lower than control (p , 0.05),
indicating that the amount of fibrosis was highest in
irreversibly dysfunctional regions.
Adenonucleotides (Table 2). Adenonucleotide contents
were similar in control regions and myocardium with
reversible dysfunction but reduced in irreversibly dysfunc-
tional myocardium. Mitochondrial function estimated by
ATP/ADP ratio and energy charge, that is, (ATP 1
one-half ADP)/(ATP1ADP1AMP), was preserved in
myocardium with reversible dysfunction but not in myocar-
dium with irreversible dysfunction.
Glycogen (Table 2). Total glycogen content/NCP was not
significantly different between regions. Acid extractable
glycogen, which is the most sensitive fraction of glycogen
for detection of acute ischemia (29), was preserved in
myocardium with reversible dysfunction but reduced in
irreversibly dysfunctional myocardium. Content of protein
bound glycogen was higher in irreversibly dysfunctional
myocardium than it was in control regions. The ratio of acid
extractable to protein bound glycogen was reduced in
regions of irreversible dysfunction. There was no correlation
between total glycogen content and MBF or FDG uptake.
Lactate (Table 2). Lactate content did not differ from
control regions in reversibly dysfunctional myocardium. In
irreversibly dysfunctional myocardium lactate, content was
significantly higher than control. Lactate content in control
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regions differed between groups and was higher for patients
with irreversible dysfunction.
Histological study (Fig. 2, A to D). Of the four patients
studied two displayed reversible dysfunction on postopera-
tive follow-up. Myocyte morphology was heterogeneous in
all regions; myocytes with glycogen accumulation and myo-
cytes appearing normal were seen in control, reversibly and
irreversibly dysfunctional myocardium. There was no appar-
ent difference in glycogen content between regions. In
irreversibly dysfunctional myocardium the degree of fibrosis
was increased.
DISCUSSION
The results of this study showed that metabolites and energy
stores were preserved in chronic reversibly dysfunctional
myocardium in contrast with irreversibly dysfunctional
myocardium. Glycogen levels revealed similar total contents
in all regions, but the composition of the glycogen pool was
altered in chronic irreversibly dysfunctional myocardium.
Perfusion in dysfunctional myocardium. It is unknown
whether chronic reversibly dysfunctional myocardium is
caused by chronic hypoperfusion (“hibernation”) or repeti-
Figure 1. Upper panel: Partial volume corrected myocardial blood flow (ml/g/min) in biopsy regions in patients with reversible dysfunction (circles, n 5
11) and irreversible dysfunction (squares, n 5 12). Mean 6 standard deviation is shown for each type of region. *p , 0.05 (two-way repeated measures
analysis of variance, test for interaction, i.e., differences (control-dysfunctional myocardium) in the reversibly dysfunctional group versus differences in the
irreversibly dysfunctional group). Ninety-five percent confidence intervals for the mean difference between dysfunctional and control regions: patients with
reversible dysfunction: (20.20; 20.05 ml/g/min). Patients with irreversible dysfunction: (20.33; 20.14 ml/g/min). Lower panel: Relative FDG uptake (%)
in biopsy regions in patients with reversible dysfunction (circles, n 5 11) and irreversible dysfunction (squares, n 5 12). Mean 6 standard deviation is
shown for each type of region. †p , 0.001. Ninety-five percent confidence intervals for the mean difference between dysfunctional and control regions:
patients with reversible dysfunction: (216; 10%). Patients with irreversible dysfunction: (257; 227%). FDG 5 18F-fluoro-2-deoxyglucose.
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tive episodes of myocardial stunning (4,30). In our patients
MBF was reduced on average by 14% in reversibly dysfunc-
tional and by 33% in irreversibly dysfunctional regions
consistent with previous reports (2–4,8). It has been sus-
pected that PET may underestimate MBF in reversibly
dysfunctional regions because the recovery of counts from
positron emitting isotopes is decreased when systolic wall
thickening is reduced (10), which is known as the partial
volume effect. Correction for partial volume did not alter the
differences in MBF between regions in this study. We
estimated MBF using 13N-ammonia, which measures aver-
age perfusion in the whole myocardial region including scar
tissue. However, when we corrected for differences between
regions in the degree of fibrosis, measured in biopsies,
perfusion did not differ between control regions and chronic
reversibly dysfunctional myocardium but remained reduced
in irreversibly dysfunctional myocardium. Similar observa-
tions have been gained by the use of 15O-water PET, which
provides values of MBF per gram of perfusable tissue, that
is, in the nonfibrotic compartment of the myocardium
(2,31). Our findings indicate that abnormal resting perfu-
sion per se cannot account for the dysfunction observed in
myocardial regions exhibiting functional recovery after re-
vascularization. This observation is compatible with a state
of repetitive ischemic episodes separated by periods of
normal perfusion as the cause of contractile dysfunction
(4,5).
In one patient MBF was only 0.41 ml/g/min in the
control region. However, the distribution of MBF in
myocardium with normal contractile function is known to
display a wide distribution with values ranging from 0.2 to
2.0 ml/g/min (2,32,33). The average MBF value in control
regions in this study is similar to findings by others (33,34).
Adenonucleotides in chronic reversibly dysfunctional
myocardium. Disturbances of myocardial energy metabo-
lism in reversibly dysfunctional myocardium have been
suspected due to alterations of the morphology of mito-
chondria and glycogen accumulation (14,17,19). Flameng et
al. (35) found reduced content of adenonucleotides in
myocardium supplied by a high-grade stenotic artery with-
out electrocardiographic signs of previous infarction. How-
ever, patients were included irrespective of preoperative wall
motion score, and no follow-up examination of the patients
was performed after revascularization to assess functional
outcome in dysfunctional regions. Animal studies show that
myocardial high-energy phosphates and ATP/ADP ratio
are unaltered in myocardium with reversible dysfunction
(36). Noninvasive measurements of ATP performed by 31P
magnetic resonance spectroscopy in humans (37) also indi-
cate that contents of adenonucleotides are preserved in
reversibly dysfunctional myocardium in contrast with irre-
versibly dysfunctional myocardium. Our findings support
that myocytes in chronic reversibly dysfunctional regions
maintain normal mitochondrial function in contrast with
myocytes in irreversibly dysfunctional myocardium.
Table 2. NCP, Adenonucleotides, Glycogen and Lactate in Myocardial Biopsies
Patients With Reversible Dysfunction
(n 5 11)
Patients With Irreversible Dysfunction
(n 5 14)
Control Reversible Dysfunction Control Irreversible Dysfunction
NCP
(mg NCP/mg ww) 130 6 23 114 6 16 (236; 1) p 121 6 44 91 6 33 (245; 215)
Adenonucleotides
ATP (nmol/mg NCP) 25.1 6 7.5 24.4 6 8.1 (25.9; 4.4) † 23.0 6 11.1 11.4 6 9.5 (215.5; 27.5)
ADP (nmol/mg NCP) 10.9 6 2.2 11.0 6 3.5 (21.2; 1.2) 10.8 6 2.9 7.7 6 4.4 (24.6; 21.5)
AMP (nmol/mg NCP) 2.9 6 1.7 3.3 6 2.1 (20.6; 1.3) 2.7 6 1.4 3.6 6 1.9 (20.3; 1.9)
ATP1ADP1AMP (nmol/mg NCP) 35.7 6 13.7 38.6 6 9.2 (25.1; 4.5) † 36.6 6 13.1 22.7 6 14.2 (218.0; 29.3)
(nmol/mg wet weight) 4.8 6 2.0 4.4 6 1.4 (21.3; 0.9) † 4.2 6 1.3 2.1 6 1.4 (22.9; 21.3)
ATP/ADP (ratio) 2.4 6 0.7 2.4 6 1.1 (20.5; 0.6) † 2.3 6 0.9 1.5 6 0.9 (21.2; 20.5)
Energy charge (ratio) 0.78 6 0.07 0.77 6 0.09 (20.06; 0.04) † 0.76 6 0.07 0.64 6 0.10 (20.19; 20.06)
Glycogen
Total glycogen (nmol/mg NCP) 632 6 148 631 6 174 (294; 95) 593 6 127 579 6 265 (2149; 135)
(nmol/mg wet weight) 83 6 16 83 6 20 (215; 15) † 77 6 28 44 6 21 (18; 48)
Acid extractable glycogen
(nmol/mg NCP)
409 6 150 404 6 117 (270; 61) † 361 6 129 252 6 223 (2180; 240)
Protein bound glycogen
(nmol/mg NCP)
223 6 102 227 6 55 (289; 80) 232 6 48 327 6 126 (2198; 220)
Acid extractable/protein bound
glycogen (ratio)
1.90 6 0.72 1.82 6 0.48 (20.61; 0.45) † 1.62 6 0.41 0.81 6 0.61 (21.10; 20.44)
Lactate
(nmol/mg NCP) 52 6 29§ 59 6 27 (24; 19) *‡ 89 6 24 114 6 52 (7; 43)
Mean 6 SD. (;): 95% confidence interval for the mean difference within groups.
*p , 0.05 (test for main effect between control and dysfunctional myocardium 5 control vs. dysfunctional myocardium [pooled data from both groups]); †p , 0.05 (test for
interaction 5 differences [control 2 dysfunctional myocardium] in the reversibly dysfunctional group vs. differences in the irreversibly dysfunctional group); ‡p , 0.05 (test for
main effect between groups 5 reversibly vs. irreversibly dysfunctional group [pooled data from control and dysfunctional myocardium in each group]); §p , 0.01 versus control
region in irreversibly dysfunctional group.
NCP 5 noncollagen protein.
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Myocardial glycogen stores. Morphological studies have
demonstrated increased PAS-stained glycogen deposits in
chronic reversibly dysfunctional myocardium (4,14,16,17).
Activity of glycogen synthase is increased in short-term
“hibernating” and repetitively ischemic myocardium
(38,39), but glycogen is merely replenished to subnormal
levels in these animal studies (38,39). Glycogen accumula-
tion is neither a consistent nor a specific finding in reversibly
dysfunctional myocardium (15,18). Shivalkar et al. (19)
reported that biopsies from dysfunctional regions with the
best postoperative recovery of myocardial function had
glycogen content similar to control regions and later con-
firmed this observation under experimental conditions (36).
We used a quantitative method for measurement of myo-
cardial glycogen content and found that total glycogen
content was similar in control and reversibly dysfunctional
regions. Our findings imply that “supercompensation” of
myocardial glycogen stores does not take place in chronic
reversibly dysfunctional regions, suggesting that glucose
uptake in these regions is used for energy generation.
Nonoxidative glycolysis in reversibly dysfunctional myo-
cardium. Consistent with previous reports (1–3) we found
similar FDG uptake in chronic reversibly dysfunctional
myocardium and control regions. Although tissue levels of
metabolites and energy stores yield no information on
metabolic turnover rates (39,40), accumulation of myocar-
dial lactate content reflects anaerobic glycolysis and provides
additional information about metabolism in the myocar-
dium. The absence of lactate accumulation in our study does
not support that anaerobic glucose metabolism is increased
in regions with reversible dysfunction.
Myocardial contents of energy stores and lactate differ-
entiate reversibly from irreversibly dysfunctional myocar-
dium. In irreversibly dysfunctional myocardium, levels of
adenonucleotides were reduced and levels of lactate in-
creased. In addition the reduction of acid extractable (i.e.,
macromolecular) glycogen and increment of protein bound
glycogen suggests exposure to ischemia since the macromo-
lecular glycogen pool is most susceptible to degradation
during ischemia (29) and is converted into low molecular
proglycogen (41,42). Thus, in contrast with reversibly
dysfunctional myocardium, metabolism was altered in irre-
versibly dysfunctional myocardium, in line with magnetic
resonance spectroscopic findings (37). This may partly be
explained by differences in perfusion because MBF per
myocyte appears lower in irreversibly dysfunctional myocar-
dium compared with reversibly dysfunctional myocardium
(2,31). It may also be secondary to the more extensive left
ventricular dilatation for patients with irreversible dysfunc-
tion since remodeling of the left ventricle affects myocardial
energy metabolism (43,44). This also explains that anaero-
bic glycolysis was increased in control regions of patients
with irreversible dysfunction due to more extensive left
Figure 2. (A) Periodic acid Schiff stained histological section from control region with normal wall motion. (B) Periodic acid Schiff stained histological
section from reversibly dysfunctional myocardium. In both regions myocytes with glycogen accumulation (arrow) and myocytes appearing normal were
observed. There was no apparent difference in glycogen content between regions. (C) Biopsy from irreversibly dysfunctional myocardium stained with
picrosirius red. The degree of fibrosis (red) is increased, and the amount of myocytes (yellow) is reduced. (D) Biopsy from control region with normal wall
motion stained with picrosirius red.
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ventricular dilatation and remodeling than in patients with
reversible dysfunction (45).
Clinical implications. It is unknown whether a state of
reversibility can be maintained for an indefinite period of
time since a prolonged period of dysfunction may deterio-
rate myocardial integrity and impair functional outcome
(17,46), possibly due to superimposed attacks of severe
ischemia. We observed that derangement in metabolism
predicted functional outcome after revascularization, but it
remains to be studied whether a transition from reversible to
irreversible myocardial dysfunction is initiated or accompa-
nied by changes in energy metabolism.
Study limitations. The use of NCP as a reference for
myocardial content of energy stores may affect the results
due to depletion of myocytic protein in dysfunctional
regions (4,14–17,19). This error is negligible compared
with that introduced using wet or dry weight as reference
(27). We used NCP and not dry weight as reference because
the amount of connective tissue varies more between regions
than the percentage of cells with sarcomere loss (14–16,19).
Different contents of metabolites in the outer and inner
layers of the myocardium may be obscured in a transmural
biopsy. However, even minor changes in endocardial con-
tent of metabolites can be detected in a transmural biopsy
(47).
Patients with regional improvement in myocardial func-
tion after revascularization had no beneficial effect on global
left ventricular function. This observation is similar to the
findings by some groups (2) but is in contrast with others
(3). Up to 50% of the left ventricle must be dysfunctional
and viable before any increase in global left ventricular
function can be detected after revascularization (1,48).
Conclusions. Contents of metabolic energy stores and
lactate in chronic reversibly dysfunctional myocardium were
preserved. In contrast, energy stores were depleted in myocar-
dium without functional recovery after revascularization.
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